Parkinson’s drug opicapone launches in the UK and Germany

News

Author: Parkinson's Life editorsPublished: 21 October 2016

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Parkinson’s drug opicapone is now available in the UK and Germany as a once-daily dose, following authorisation by the European Commission (EC).

Produced by BIAL under the brand name ‘Ongentys’, opicapone is in a class of drugs known as ‘COMT inhibitors’, which can extend the therapeutic effects of levodopa.

It is intended for use by Parkinson’s patients who experience end-of-dose motor complications such as “wearing-off” from long-term levodopa use.

Professor Andrew Lees, Professor of Neurology, University College London, said: “There is still an unmet medical need for effective new therapeutic options for Parkinson’s disease. Opicapone will provide clinicians in UK with a COMT inhibitor, with the convenience of once-daily dosing.”

The results of a phase III clinical trial involving 600 patients across in Europe was published in the ‘The Lancet Neurology in December 2015’, and the drug was approved for use by the EC in July 2016.

Go Back

Share this story

Comments


Related articles


A man sits at a computer holding a mug

Europe

Take part in a survey to help improve DBS technology

The survey is available in four countries

READ MORE
A composite image of Robbie Tucker and Heather Kennedy.

Episodes

Podcast: Love, sex and Parkinson’s

Exploring the impact of Parkinson’s disease on dating and relationships

READ MORE
Techno-help-PD

Advances

Moving to the beat: can techno help Parkinson’s patients walk better?

Here’s a good excuse for blasting out your favourite dance music

READ MORE